PxPixel
+612 9045 4394
 
CHECKOUT
Molecular Biology of Cancer : Advanced Texts - Fiona Macdonald

Molecular Biology of Cancer

Advanced Texts

Paperback Published: 25th March 2004
ISBN: 9781859962473
Number Of Pages: 269

Share This Book:

Paperback

RRP $191.99
$140.90
27%
OFF
or 4 easy payments of $35.23 with Learn more
Ships in 7 to 10 business days

Earn 282 Qantas Points
on this Book

Molecular Biology of Cancer has been extensively revised and covers heredity cancer, microarray technology and increased study of childhood cancers.  It continues to provide a detailed overview of the process which lead to the development and proliferation of cancer cells, including the techniques available for their study.  It also describes the means by which tumor suppressor genes and oncogenes may be used in the diagnosis and in determining the prognosis of a wide variety of cancers, including breast, genitourinary, lung and gastrointestinal cancer.

Industry Reviews

.."."A worthwhile addition to a collection serving biology or premed students involved in cancer research as well as clinical labs."
."
Vol. 8, # 4
-E-Streams, April 2005

Abbreviationsp. xi
Prefacep. xv
General principlesp. 1
Introductionp. 1
What is cancer?p. 1
The cell cyclep. 2
Apoptosisp. 4
Chromosomes and cancerp. 6
Inherited vs. sporadic cancerp. 6
The multistage nature of cancer developmentp. 9
Referencesp. 10
Oncogenesp. 11
Viruses and cancerp. 11
Cellular oncogenesp. 13
Function of the proto-oncogenesp. 15
Mechanisms of oncogene activationp. 26
Oncogenes in human tumorsp. 29
Referencesp. 30
Tumor suppressor genesp. 31
Introductionp. 31
Evidence for the existence of tumor suppressor genesp. 33
Suppression of malignancy by cell fusionp. 33
Tumor suppressor genes in hereditary cancers: the retinoblastoma modelp. 34
Retinoblastoma - RB1p. 37
Cell cycle regulation of RBp. 38
RB/E2F pathwayp. 39
RB and apoptosisp. 40
RB in human cancersp. 40
TP53 (p53)p. 41
The TP53 gene and its protein product p53p. 41
Activation of TP53p. 42
Activated p53 responses - cell cycle inhibitionp. 44
Activated p53 responses - apoptosisp. 45
Other functions of activated p53p. 45
Mutations of p53p. 46
APCp. 47
The APC gene and its protein productp. 47
Function of the APC proteinp. 48
Mutations in APCp. 50
BRCA1 and BRCA2p. 50
The BRCA1 and 2 genes and their protein productsp. 50
Mutations in BRCA1 and 2p. 52
WT1p. 53
NF1 and NF2p. 54
NF1p. 54
NF2p. 55
VHLp. 55
TSC1 and TSC2p. 56
PTCHp. 56
Interaction and differences between oncogenes and tumor suppressor genesp. 57
Referencesp. 58
Cell cycle control genes and mismatch repair genesp. 61
Introductionp. 61
Cyclins and cyclin-dependent kinasesp. 61
Cyclin-dependent kinase inhibitorsp. 63
Progression and control of the cell cyclep. 64
Cyclins, CDKs and CKIs in cancerp. 68
Mismatch repair genesp. 68
Referencesp. 72
Hereditary cancersp. 75
Introductionp. 75
Inherited cancer syndromesp. 75
Procedures for genetic testingp. 75
Familial colon cancerp. 76
Familial adenomatous polyposis (FAP)p. 77
Hereditary nonpolyposis colon cancer (HNPCC)p. 80
Other syndromes predisposing to colorectal cancerp. 82
Familial breast and breast/ovarian cancerp. 84
BRCA1 and BRCA2p. 85
Other syndromes predisposing to breast cancerp. 86
Li-Fraumeni syndrome (LFS)p. 87
Multiple endocrine neoplasiap. 88
Multiple endocrine neoplasia type 1 (MEN1)p. 88
Multiple endocrine neoplasia type 2 (MEN2)p. 88
Von Hippel Lindau syndrome (VHL)p. 89
Familial renal cell cancerp. 90
Familial paragangliomap. 90
Neurofibromatosesp. 91
Neurofibromatosis type 1 (NF1)p. 91
Neurofibromatosis type 2 (NF2)p. 91
Gorlin syndromep. 92
Tuberous sclerosisp. 93
Familial gastric cancerp. 93
Familial melanomap. 94
Hereditary prostate cancerp. 95
Conclusionp. 95
Referencesp. 95
Lung cancerp. 99
Introductionp. 99
Pathologyp. 99
Small-cell lung cancer (SCLC)p. 99
Nonsmall-cell lung cancer (NSCLC)p. 100
Clinical featuresp. 103
Genetic factors and individual susceptibilityp. 105
Molecular alterations in lung cancerp. 105
Tumor suppressor genesp. 106
Oncogenesp. 107
Growth factors and receptorsp. 107
Mesotheliomap. 108
Multiple primary tumors of the upper aerodigestive tractp. 108
Implications for therapyp. 108
Referencesp. 109
Colorectal cancerp. 111
Introductionp. 111
The adenoma-carcinoma sequencep. 112
Genetic changes in sporadic colorectal cancer - the role of oncogenesp. 113
MYCp. 113
RASp. 113
Other oncogenesp. 115
Genetic changes in sporadic colorectal cancer - the role of tumor suppressor genesp. 115
p53p. 115
Adenomatous polyposis coli gene (APC)p. 117
SMADp. 118
MCCp. 118
NM23p. 118
Other changesp. 119
Mismatch repair defectsp. 119
TGF[beta]p. 120
Cell cycle regulatorsp. 120
Referencesp. 120
Gastrointestinal cancerp. 123
Introductionp. 123
Pathology of esophagogastric cancerp. 123
Esophageal cancerp. 123
Barrett's esophagusp. 123
Gastric cancerp. 126
Epidemiology of esophagogastric malignancyp. 126
Cellular and molecular alterations in esophagogastric cancerp. 127
Cell cycle regulationp. 127
Epithelial proliferation markersp. 128
Aneuploidyp. 128
Chromosomal aberrationsp. 128
Loss of heterozygosityp. 129
Tumor suppressor genesp. 129
p53p. 129
Retinoblastoma (RB)p. 131
p16p. 132
p14p. 132
Fragile histidine triad (FHIT) genep. 132
Adenomatous polyposis coli (APC) genep. 132
Growth factors and receptorsp. 133
Oncogenesp. 133
Cyclin D1p. 133
RASp. 134
DNA repair-associated genesp. 134
Microsatellite instabilityp. 135
Hereditary factorsp. 135
Cancers of the small intestinep. 135
Pancreatic cancerp. 136
Hepatobiliary cancerp. 136
Hepatocellular carcinomap. 136
Intrahepatic cholangiocarcinomap. 137
Extrahepatic bile duct and gallbladder cancerp. 137
Hepatoblastomap. 137
Referencesp. 138
Breast cancerp. 141
Introductionp. 141
Genetic changes in breast cancerp. 142
MYCp. 142
ERBB2 and RASp. 144
p53p. 146
BRCA1 and BRCA2p. 148
CCND1p. 150
RB1p. 151
Other chromosomal abnormalities and potential tumor suppressorsp. 151
Estrogens and cell cycle regulationp. 152
Male breast cancerp. 152
Gene expression profilingp. 152
Referencesp. 153
Genitourinary cancerp. 157
Ovarian and endometrial cancersp. 157
Cervical cancerp. 161
Testicular cancerp. 163
Renal cell cancer and bladder cancerp. 163
Prostate cancerp. 167
Referencesp. 170
Leukemia and lymphomap. 173
Introductionp. 173
TEL/JAK2p. 175
MYCp. 175
BCL1 and BCL2p. 176
ABL/BCRp. 178
AML1/CBF[beta]/ETO(MTG8)p. 181
TLS/ERGp. 182
PML/RAR[alpha]p. 182
ALL-1 and 11q23 translocationsp. 182
RBTN T cell oncogenesp. 183
Cyclin-dependent kinase 4 inhibitor, CDKN2 (p16/MTS1/INK4a)p. 183
RASp. 183
p53p. 184
MDM2p. 184
Detection of minimal residual disease (MRD)p. 185
Refining the classification of leukemias and lymphomasp. 186
Referencesp. 188
Childhood solid tumorsp. 191
Introductionp. 191
Retinoblastomap. 191
Wilms' tumorp. 192
Neuroblastomap. 194
Rhabdomyosarcomap. 197
Ewing's sarcomap. 198
Referencesp. 200
Therapeutic applicationsp. 203
Introductionp. 203
Receptors as targetsp. 203
Receptor tyrosine kinases - ERBBp. 203
BCR-ABLp. 204
Estrogen receptor (ER)p. 204
Retinoic acid receptor (RAR) and retinoid X receptor (RXR)p. 205
Peroxisome proliferator-activated receptor [gamma] (PPAR[gamma])p. 205
Immunologic interventionp. 206
Vaccinesp. 206
Antibodiesp. 210
Immune cellsp. 213
Cytokinesp. 215
Other targetsp. 216
Proteasomesp. 216
p53p. 216
Raf kinasesp. 218
Cyclin-dependent kinases (CDKs)p. 218
Angiogenesisp. 218
Epigenetic silencingp. 221
Mitochondriap. 221
Carbohydratesp. 222
Cyclooxygenase 2 (COX-2)p. 222
Antisense RNA or oligonucleotidesp. 223
RNA interference/inhibition (RNAi)p. 225
Gene therapyp. 225
Drug discovery and drug designp. 228
Conclusions and future prospectsp. 229
Referencesp. 231
Molecular techniques for analysis of genesp. 235
Introductionp. 235
Analysis of DNA or RNAp. 236
Genetic markersp. 236
Polymerase chain reaction (PCR)p. 238
Mutation detection techniquesp. 239
Southern blottingp. 246
Gene tracking with RFLPs and microsatellitesp. 248
Single nucleotide polymorphisms (SNPs)p. 250
Northern blottingp. 252
In situ hybridizationp. 252
Comparative genomic hybridizationp. 252
DNA microarraysp. 252
Real-time (kinetic) RT-PCRp. 255
Analysis of proteinsp. 256
Production of antibodies to onco- or tumor suppressor proteinsp. 256
Western blottingp. 257
Immunohistochemical techniquesp. 257
Flow cytometryp. 258
Proteomicsp. 261
Tissue microarraysp. 262
Referencesp. 262
Indexp. 265
Table of Contents provided by Rittenhouse. All Rights Reserved.

ISBN: 9781859962473
ISBN-10: 1859962475
Series: Advanced Texts
Audience: Professional
Format: Paperback
Language: English
Number Of Pages: 269
Published: 25th March 2004
Publisher: Bios Scientific Publishers Ltd
Country of Publication: GB
Dimensions (cm): 24.13 x 17.15  x 1.27
Weight (kg): 0.57
Edition Number: 2
Edition Type: New edition

Earn 282 Qantas Points
on this Book